mk 0663 has been researched along with Disease Models, Animal in 25 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 7 (28.00) | 29.6817 |
| 2010's | 14 (56.00) | 24.3611 |
| 2020's | 4 (16.00) | 2.80 |
| Authors | Studies |
|---|---|
| Boulet, L; Brideau, C; Claveau, D; Côté, B; Ducharme, Y; Ethier, D; Frenette, R; Friesen, RW; Gagnon, M; Giroux, A; Guay, J; Guiral, S; Mancini, J; Martins, E; Massé, F; Méthot, N; Riendeau, D; Rubin, J; Xu, D; Yu, H | 1 |
| Beswick, PJ; Bingham, S; Bountra, C; Carter, MC; Chambers, LJ; Chessell, IP; Clayton, NM; Collins, SD; Corfield, JA; Gleave, RJ; Green, RH; Hartley, CD; Kleanthous, S; Lambeth, PF; Lucas, FS; Mathews, N; Naylor, A; Page, LW; Payne, JJ; Pegg, NA; Price, HS; Skidmore, J; Stevens, AJ; Stocker, R; Stratton, SC; Stuart, AJ; Swarbrick, ME; Wiseman, JO | 1 |
| Bashir, R; Hameed, AD; Javed, K; Ovais, S; Rathore, P; Samim, M; Yaseen, R; Yaseen, S | 1 |
| Abrams, RPM; Bachani, M; Balasubramanian, A; Brimacombe, K; Dorjsuren, D; Eastman, RT; Hall, MD; Jadhav, A; Lee, MH; Li, W; Malik, N; Nath, A; Padmanabhan, R; Simeonov, A; Steiner, JP; Teramoto, T; Yasgar, A; Zakharov, AV | 1 |
| Chang, YC; Chen, WF; Hsieh, SP; Hsuan Jean, Y; Lee, CH; Lee, HP; Lin, YY; Sung, CS; Tang, CC; Wen, ZH | 1 |
| Chen, G; He, J; Ji, C; Jiang, H; Liang, T; Liu, B; Luo, Z; Shao, Y | 1 |
| Agnes, JP; Báfica, A; Bishop, AJR; Bruxel, MA; Casagrande, T; Cassali, GD; das Neves, RN; Delgobo, M; Falchetti, M; Garcia, APV; Gelain, DP; Gonçalves, RM; Mendes, DAGB; Moreira, JCF; Rafacho, A; Somensi, N; Vieira, TC; Zanotto-Filho, A | 1 |
| Agarwal, M; Chugh, PK; Gupta, M; Tekur, U | 1 |
| Assreuy, J; Fernandes, D; Machado, WM; Mendes, RT; Olchanheski, LR; Santos, FA; Sordi, R; Stanczyk, CP | 1 |
| Aksoy, M; Albayrak, A; Demirci, E; Gundogdu, C; Kurt, N; Suleyman, B | 1 |
| Citraro, R; De Sarro, G; Leo, A; Marra, R; Russo, E | 1 |
| Ghosh, T; Sil, S | 2 |
| Arora, SK; Khanduja, KL; Medhi, B; Pandhi, P; Rao, RS; Saikia, UN; Toor, JS | 1 |
| Kaur, J; Saini, MK; Sanyal, SN; Sharma, P | 1 |
| Almeida, A; Baltazar, F; Castro, AG; Cruz, A; Lamas, N; Lima-Rodrigues, M; Oliveira, P; Pedrosa, J; Reis, RM; Valle-Fernandes, A; Vieira, A | 1 |
| Anitha, T; Gajera, K; Jayaraman, R; Joshi, VD; Ladani, K; Manisenthil, KT; Palei, NN | 1 |
| Fracon, RN; Lamano, T; Moris, IC; Teófilo, JM | 1 |
| Aguiar, JA; Benevides, NM; Bezerra, MM; Brito, GA; Chaves, HV; da Graça, JR; Grangeiro, NM; Lima, V; Silva, AA | 1 |
| Aggarwal, S; Bhateja, D; Dhull, DK; Dhull, RK; Jindal, A; Padi, SS | 1 |
| Sanyal, SN; Setia, S | 2 |
| Boulet, J; Gottshall, S; Harrison, J; Mark, L; Pearson, M; Walker, K; Whiteside, GT | 1 |
| Kulkarni, SK; Patil, CS; Singh, VP | 1 |
| Bernardi, RM; Dalmora, SL; Ferretto, RM; Fronza, M; Sangoi, MS; Wrasse, M | 1 |
25 other study(ies) available for mk 0663 and Disease Models, Animal
| Article | Year |
|---|---|
Substituted phenanthrene imidazoles as potent, selective, and orally active mPGES-1 inhibitors.
Topics: Analgesics, Non-Narcotic; Animals; Disease Models, Animal; Drug Design; Guinea Pigs; Humans; Hyperalgesia; Imidazoles; Inhibitory Concentration 50; Intramolecular Oxidoreductases; Molecular Structure; Phenanthrenes; Prostaglandin-E Synthases; Rats; Structure-Activity Relationship | 2007 |
Identification of [4-[4-(methylsulfonyl)phenyl]-6-(trifluoromethyl)-2-pyrimidinyl] amines and ethers as potent and selective cyclooxygenase-2 inhibitors.
Topics: Amines; Animals; Brain; Chemistry, Pharmaceutical; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Disease Models, Animal; Drug Design; Ethers; Humans; Inflammation; Inhibitory Concentration 50; Mice; Molecular Structure; Neurodegenerative Diseases; Pyrimidines; Rats; Sulfones | 2009 |
Synthesis, antiproliferative and anti-inflammatory activities of some novel 6-aryl-2-(p-(methanesulfonyl)phenyl)-4,5-dihydropyridazi-3(2H)-ones.
Topics: Animals; Anti-Inflammatory Agents; Antineoplastic Agents; Carrageenan; Cell Line, Tumor; Cell Proliferation; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Edema; Female; Humans; Male; Molecular Structure; Pyridazines; Rats; Rats, Wistar; Structure-Activity Relationship | 2013 |
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
Topics: Animals; Antiviral Agents; Artificial Intelligence; Chlorocebus aethiops; Disease Models, Animal; Drug Evaluation, Preclinical; High-Throughput Screening Assays; Immunocompetence; Inhibitory Concentration 50; Methacycline; Mice, Inbred C57BL; Protease Inhibitors; Quantitative Structure-Activity Relationship; Small Molecule Libraries; Vero Cells; Zika Virus; Zika Virus Infection | 2020 |
The COX-2 inhibitor etoricoxib reduces experimental osteoarthritis and nociception in rats: The roles of TGF-β1 and NGF expressions in chondrocytes.
Topics: Animals; Chondrocytes; Cyclooxygenase 2 Inhibitors; Disease Models, Animal; Etoricoxib; Nerve Growth Factor; Nociception; Osteoarthritis; Rats; Transforming Growth Factor beta1 | 2020 |
Etoricoxib decreases subchondral bone mass and attenuates biomechanical properties at the early stage of osteoarthritis in a mouse model.
Topics: Animals; Biomechanical Phenomena; Bone Density; Disease Models, Animal; Etoricoxib; Knee Joint; Male; Mice; Mice, Inbred C57BL; Microscopy, Atomic Force; Osteoarthritis; X-Ray Microtomography | 2020 |
COX-2 promotes mammary adipose tissue inflammation, local estrogen biosynthesis, and carcinogenesis in high-sugar/fat diet treated mice.
Topics: 9,10-Dimethyl-1,2-benzanthracene; Animals; Aromatase; Breast Neoplasms; Cell Line, Tumor; Chemokine CCL2; Cyclooxygenase 2; Diet, High-Fat; Dinoprostone; Disease Models, Animal; Etoricoxib; Female; Gene Expression Regulation, Neoplastic; Humans; Interleukin-6; MCF-7 Cells; Medroxyprogesterone Acetate; Mice; Sugars; Up-Regulation | 2021 |
Etoricoxib attenuates effect of antihypertensives in a rodent model of DOCA-salt induced hypertension.
Topics: Animals; Antihypertensive Agents; Atenolol; Benzimidazoles; Benzoates; Blood Pressure; Cyclooxygenase 2 Inhibitors; Desoxycorticosterone Acetate; Disease Models, Animal; Etoricoxib; Hypertension; Mineralocorticoids; Pyridines; Ramipril; Rats; Rats, Sprague-Dawley; Sodium Chloride; Sulfones; Telmisartan | 2013 |
Periodontitis increases vascular cyclooxygenase-2: potential effect on vascular tone.
Topics: Alveolar Bone Loss; Animals; Anti-Inflammatory Agents; Arterial Pressure; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Disease Models, Animal; Endothelium, Vascular; Etoricoxib; Heart Rate; Male; Mesenteric Arteries; Nitric Oxide; Periodontitis; Pyridines; Random Allocation; Rats, Wistar; Sulfones; Vasoconstrictor Agents; Vasodilator Agents | 2014 |
The effect of etoricoxib on kidney ischemia-reperfusion injury in rats: a biochemical and immunohistochemical assessment.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Caspase 3; Cells, Cultured; Cyclooxygenase 2; Disease Models, Animal; Etoricoxib; Gene Expression Regulation; Humans; Kidney; Male; Malondialdehyde; Oxidative Stress; Peroxidase; Proto-Oncogene Proteins c-bcl-2; Pyridines; Rats; Rats, Wistar; Reperfusion Injury; Sulfones | 2014 |
Antiepileptogenic effects of the selective COX-2 inhibitor etoricoxib, on the development of spontaneous absence seizures in WAG/Rij rats.
Topics: Animals; Anticonvulsants; Brain; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Disease Models, Animal; Electroencephalography; Epilepsy, Absence; Etoricoxib; Female; Male; Motor Activity; Pyridines; Rats; Rats, Wistar; Sulfones | 2015 |
Role of cox-2 mediated neuroinflammation on the neurodegeneration and cognitive impairments in colchicine induced rat model of Alzheimer's Disease.
Topics: Alzheimer Disease; Analysis of Variance; Animals; Cognition Disorders; Colchicine; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cytokines; Dinoprostone; Disease Models, Animal; Dose-Response Relationship, Drug; Encephalitis; Etoricoxib; Injections, Intraventricular; Male; Maze Learning; Neurodegenerative Diseases; Plaque, Amyloid; Pyridines; Rats; Sulfones; Time Factors | 2016 |
Cox-2 Plays a Vital Role in the Impaired Anxiety Like Behavior in Colchicine Induced Rat Model of Alzheimer Disease.
Topics: Alzheimer Disease; Animals; Anxiety; Behavior, Animal; Colchicine; Corticosterone; Cyclooxygenase 2; Disease Models, Animal; Etoricoxib; Male; Memory; Pyridines; Rats; Sulfones | 2016 |
Experimentally induced various inflammatory models and seizure: understanding the role of cytokine in rat.
Topics: Acetic Acid; Analysis of Variance; Animals; Arthritis; Colitis; Cyclooxygenase Inhibitors; Cytokines; Disease Models, Animal; DNA Fragmentation; Etoricoxib; Freund's Adjuvant; Immunosuppressive Agents; Inflammation; Male; Pyridines; Rats; Rats, Wistar; Seizures; Sulfones; Thalidomide | 2008 |
The cyclooxygenase-2 inhibitor etoricoxib is a potent chemopreventive agent of colon carcinogenesis in the rat model.
Topics: 1,2-Dimethylhydrazine; Adenoma; Animals; Anticarcinogenic Agents; Apoptosis; Biomarkers; Colonic Neoplasms; Cyclooxygenase 2 Inhibitors; Disease Models, Animal; Etoricoxib; Immunohistochemistry; In Situ Nick-End Labeling; Male; Pyridines; Rats; Rats, Sprague-Dawley; Sulfones | 2009 |
The selective COX-2 inhibitor Etoricoxib reduces acute inflammatory markers in a model of neurogenic laryngitis but loses its efficacy with prolonged treatment.
Topics: Animals; Calcitonin Gene-Related Peptide; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Disease Models, Animal; Etoricoxib; Interleukin-10; Interleukin-1beta; Interleukin-6; Laryngitis; Male; Pyridines; Rats; Rats, Wistar; Substance P; Sulfones; Tumor Necrosis Factor-alpha | 2010 |
Influence of etoricoxib on anticonvulsant activity of phenytoin and diazepam in experimental seizure models in mice.
Topics: Animals; Anticonvulsants; Diazepam; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Interactions; Drug Therapy, Combination; Electricity; Etoricoxib; Male; Mice; Pentylenetetrazole; Phenytoin; Pyridines; Seizures; Sulfones | 2010 |
Treatment with paracetamol, ketorolac or etoricoxib did not hinder alveolar bone healing: a histometric study in rats.
Topics: Acetaminophen; Analgesics, Non-Narcotic; Analysis of Variance; Animals; Anti-Inflammatory Agents, Non-Steroidal; Bone Regeneration; Cyclooxygenase 1; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Disease Models, Animal; Etoricoxib; Fracture Healing; Ketorolac; Male; Pyridines; Rats; Rats, Wistar; Sulfones; Time Factors | 2010 |
Heme oxygenase/carbon monoxide-biliverdin pathway may be involved in the antinociceptive activity of etoricoxib, a selective COX-2 inhibitor.
Topics: Acetic Acid; Analgesics; Animals; Biliverdine; Carbon Monoxide; Cyclooxygenase 2 Inhibitors; Disease Models, Animal; Dose-Response Relationship, Drug; Etoricoxib; Heme Oxygenase-1; Male; Mice; Pain; Pain Measurement; Pyridines; Sulfones | 2011 |
Neuroprotective effect of cyclooxygenase inhibitors in ICV-STZ induced sporadic Alzheimer's disease in rats.
Topics: Alzheimer Disease; Animals; Antibiotics, Antineoplastic; Cyclooxygenase 2 Inhibitors; Disease Models, Animal; Etoricoxib; Injections, Intraventricular; Lipid Peroxidation; Male; Neuroprotective Agents; Pyridines; Rats; Rats, Wistar; Salicylates; Streptozocin; Sulfones | 2012 |
Nuclear factor kappa B: a pro-inflammatory, transcription factor-mediated signalling pathway in lung carcinogenesis and its inhibition by nonsteroidal anti-inflammatory drugs.
Topics: 9,10-Dimethyl-1,2-benzanthracene; Animals; Anti-Inflammatory Agents, Non-Steroidal; Apoptosis; Cell Proliferation; Chemoprevention; Disease Models, Animal; Etoricoxib; Indomethacin; Lung Neoplasms; NF-kappa B; Nitric Oxide Synthase Type II; Oxidative Stress; Pyridines; Rats; Rats, Sprague-Dawley; Reactive Oxygen Species; Signal Transduction; Sulfones; Transcription Factors | 2012 |
Upregulation of intrinsic apoptotic pathway in NSAIDs mediated chemoprevention of experimental lung carcinogenesis.
Topics: 9,10-Dimethyl-1,2-benzanthracene; Animals; Anti-Inflammatory Agents, Non-Steroidal; Apoptosis; Cyclooxygenase 1; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Disease Models, Animal; DNA Fragmentation; Etoricoxib; Female; Indomethacin; Lung Neoplasms; Pyridines; Rats; Rats, Sprague-Dawley; Reverse Transcriptase Polymerase Chain Reaction; Sulfones; Up-Regulation | 2012 |
Pharmacological characterisation of a rat model of incisional pain.
Topics: Amines; Analgesics; Animals; Behavior, Animal; Celecoxib; Cyclohexanecarboxylic Acids; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Administration Routes; Drug Administration Schedule; Drug Evaluation, Preclinical; Etoricoxib; Foot; Gabapentin; gamma-Aminobutyric Acid; Hindlimb; Hyperalgesia; Indomethacin; Male; Morphine; Muscle, Skeletal; Naproxen; Nociceptors; Pain Threshold; Pain, Postoperative; Pyrazoles; Pyridines; Rats; Rats, Sprague-Dawley; Reproducibility of Results; Sulfonamides; Sulfones; Time Factors; Weight-Bearing | 2004 |
Analysis of interaction between etoricoxib and tramadol against mechanical hyperalgesia of spinal cord injury in rats.
Topics: Animals; Disease Models, Animal; Drug Synergism; Drug Therapy, Combination; Etoricoxib; Female; Hyperalgesia; Pain Threshold; Pyridines; Rats; Rats, Wistar; Spinal Cord Injuries; Sulfones; Tramadol | 2006 |
Evaluation of the changes in hemostatic parameters induced by etoricoxib in rat model.
Topics: Animals; Aspirin; Blood Coagulation Tests; Cyclooxygenase Inhibitors; Disease Models, Animal; Etoricoxib; Factor Xa; Hemostasis; Male; Prothrombin; Pyridines; Rats; Sulfones | 2008 |